Evidence map›Paper›PMID 38038419›Full record

ArticleRadiology and oncology2023

Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM.

Maria Ingenerf, Homeira Karim, Christoph Auernhammer, Matthias Zacherl, Vera Wenter, Michael Winkelmann, Jens Ricke, Frank Berger, Christine Schmid-Tannwald

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology and oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maria IngenerfDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany.
Homeira KarimDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany.
Christoph AuernhammerENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System at the University Hospital of Munich (GEPNET-KUM), University Hospital of Munich, Munich, Germany.
Matthias ZacherlDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Vera WenterDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Michael WinkelmannDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany.
Jens RickeDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany.
Frank BergerDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany.
Christine Schmid-TannwaldDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to evaluate the predictive and monitoring role of somatostatin receptor (SSTR) positron emission tomography-computed tomography (PET/CT) and clinical parameters in patients with neuroendocrine liver metastases (NELM) from pancreatic neuroendocrine tumors (pNET) receiving capecitabine and temozolomide (CAPTEM). PATIENTS AND

methodsThis retrospective study included twenty-two patients with pNET and NELM receiving CAPTEM who underwent pre- and post-therapeutic

resultsThe median PFS (mPFS) was 7 months. Responders had a significantly longer mPFS compared to non-responders (10

conclusionsSSTR-PET/CT can be useful for predicting response and survival outcomes in pNET patients receiving CAPTEM: Higher baseline SUV values, particularly Tmax/Smean ratios of liver metastases were associated with better response and prolonged PFS.

Indexed as

Liver NeoplasmsNeuroectodermal Tumors, PrimitiveNeuroendocrine TumorsPancreatic NeoplasmsHumansPositron Emission Tomography Computed TomographyReceptors, SomatostatinRetrospective StudiesReceptors, Somatostatincapecitabine/temozolomideneuroendocrine tumorspositron emission tomography–computed tomographyprognosis

Identifiers

PMID38038419
PMCPMC10690751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.